Literature DB >> 12692113

Histopathologic extent of cervical intraepithelial neoplasia 3 lesions in the atypical squamous cells of undetermined significance low-grade squamous intraepithelial lesion triage study: implications for subject safety and lead-time bias.

Mark E Sherman1, Sophia S Wang, Robert Tarone, Laurie Rich, Mark Schiffman.   

Abstract

Cervical intraepithelial neoplasia 3 (CIN3) is the precursor of mostsquamous carcinomas and serves as a surrogate end point. However, small CIN3 lesions are rarely associated with concurrent invasion. We hypothesized that aggressive follow-up for cytology of atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL) leads predominantly to detection of smaller CIN3 lesions than those usually associated with cancer. We assessed this hypothesis in a masked histopathologic review of 330 CIN3 lesions in the ASCUS LSILTriage Study, focusing on ASCUS referrals. ASCUS referrals underwent randomized management [colposcopy for repeat cytology of high-grade squamous intraepithelial lesion (HSIL), colposcopy for oncogenic human papillomavirus (HPV) detection or repeat HSIL, or immediate colposcopy]; then all were followed with repeat cytology for 2 years, followed by colposcopy and aggressive treatment. We assessed all CIN3 lesions qualitatively and measured 39 of them. CIN3 lesions were overwhelmingly small. Compared with enrollment, lesions found at follow-up or exit involved fewer tissue fragments (P < 0.01) and showed less diffuse gland involvement (P = 0.03). CIN3 lesions found postenrollment after HPV testing involved the fewest tissue fragments [versus immediate colposcopy (P = 0.04) or repeat cytology of HSIL (P = 0.02)], and none showed diffuse gland involvement. The median distal-proximal length was 6.5 mm (median replacement of total epithelium = 5%) in the 39 measured cases. We conclude that CIN3 lesions underlying ASCUS or LSIL generally lack features associated with invasion, particularly if managed using HPV testing, suggesting that aggressive management leads to early detection of CIN3 but probably prevents relatively few cancers in screened populations.

Entities:  

Mesh:

Year:  2003        PMID: 12692113

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  22 in total

1.  Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3.

Authors:  Philip E Castle; Mark Schiffman; Cosette M Wheeler; Nicolas Wentzensen; Patti E Gravitt
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07       Impact factor: 4.254

2.  Absence of dysplasia in the excised cervix by a loop electrosurgical excision procedure in the treatment of cervical intraepithelial neoplasia.

Authors:  Aeli Ryu; Kyehyun Nam; Sooho Chung; Jeongsik Kim; Haehyeog Lee; Eunsuk Koh; Donghan Bae
Journal:  J Gynecol Oncol       Date:  2010-06-30       Impact factor: 4.401

3.  Molecular mapping of high-grade cervical intraepithelial neoplasia shows etiological dominance of HPV16.

Authors:  Jacolien van der Marel; Wim G V Quint; Mark Schiffman; Miekel M van de Sandt; Rosemary E Zuna; S Terence Dunn; Katherine Smith; Cara A Mathews; Michael A Gold; Joan Walker; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2012-04-16       Impact factor: 7.396

4.  Type-dependent association between risk of cervical intraepithelial neoplasia and viral load of oncogenic human papillomavirus types other than types 16 and 18.

Authors:  Long Fu Xi; Mark Schiffman; Yang Ke; James P Hughes; Denise A Galloway; Zhonghu He; Ayaka Hulbert; Rachel L Winer; Laura A Koutsky; Nancy B Kiviat
Journal:  Int J Cancer       Date:  2017-01-24       Impact factor: 7.396

5.  Detection of cervical cancer and its precursors by endocervical curettage in 13,115 colposcopically guided biopsy examinations.

Authors:  Julia C Gage; Máire A Duggan; Jill G Nation; Song Gao; Philip E Castle
Journal:  Am J Obstet Gynecol       Date:  2010-08-30       Impact factor: 8.661

6.  Impact of improved classification on the association of human papillomavirus with cervical precancer.

Authors:  Philip E Castle; Mark Schiffman; Cosette M Wheeler; Nicolas Wentzensen; Patti E Gravitt
Journal:  Am J Epidemiol       Date:  2009-12-10       Impact factor: 4.897

Review 7.  How to evaluate emerging technologies in cervical cancer screening?

Authors:  Marc Arbyn; Guglielmo Ronco; Jack Cuzick; Nicolas Wentzensen; Philip E Castle
Journal:  Int J Cancer       Date:  2009-12-01       Impact factor: 7.396

8.  Effect of cervical cytologic status on the association between human papillomavirus type 16 DNA load and the risk of cervical intraepithelial neoplasia grade 3.

Authors:  Long Fu Xi; Nancy B Kiviat; Denise A Galloway; Xiao-Hua Zhou; Jesse Ho; Laura A Koutsky
Journal:  J Infect Dis       Date:  2008-08-01       Impact factor: 5.226

9.  Comparative risk of high-grade histopathology diagnosis after a CIN 1 finding in endocervical curettage versus cervical biopsy.

Authors:  Julia C Gage; Máire A Duggan; Jill G Nation; Song Gao; Philip E Castle
Journal:  J Low Genit Tract Dis       Date:  2013-04       Impact factor: 1.925

10.  Comparison of two PCR-based human papillomavirus genotyping methods.

Authors:  Philip E Castle; Carolina Porras; Wim G Quint; Ana Cecilia Rodriguez; Mark Schiffman; Patti E Gravitt; Paula González; Hormuzd A Katki; Sandra Silva; Enrique Freer; Leen-Jan Van Doorn; Silvia Jiménez; Rolando Herrero; Allan Hildesheim
Journal:  J Clin Microbiol       Date:  2008-08-20       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.